Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President and CEO · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,347,543 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,372,023 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,029 · Balance 1,369,994 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,297 · Balance 1,366,697 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,981 · Balance 1,362,716 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,143 · Balance 1,359,573 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,357 · Balance 1,356,216 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,266 · Balance 1,353,950 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,214 · Balance 1,352,736 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 2,010 · Balance 1,350,726 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 573 · Balance 1,350,153 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,358 · Balance 1,348,795 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 847 · Balance 1,347,948 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 405 · Balance 1,347,543 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy SMK Trust FBO KSK | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Krish Srinivas Krishnan Trust | 77,710 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 77,710 F17: Held by the Krish Srinivas Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by SMK Trust FBO KSK, an irrevocable trust established by Mrs. Krishnan for the benefit of Mr. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Krish Srinivas Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 405 | $366.56 | $148,455.46 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 13 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,347,543 F15 · price: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 847 | $365.42 | $309,507.61 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 12 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,347,948 F14 · price: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,358 | $364.48 | $494,963.03 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 11 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,348,795 F13 · price: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 573 | $363.34 | $208,195.20 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 10 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,350,153 F12 · price: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,010 | $362.65 | $728,927.30 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,350,726 F11 · price: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,214 | $361.61 | $438,993.45 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,352,736 F10 · price: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,266 | $360.46 | $816,809.16 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,353,950 F9 · price: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,357 | $359.39 | $1,206,459.14 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,356,216 F8 · price: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,143 | $358.42 | $1,126,508.40 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,359,573 F7 · price: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,981 | $357.57 | $1,423,501.30 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,362,716 F6 · price: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,297 | $356.37 | $1,174,947.60 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,366,697 F5 · price: The transaction was executed in multiple trades ranging from $355.98 to $356.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,029 | $355.57 | $721,455.39 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,369,994 F4 · price: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 520 | $354.54 | $184,360.80 |
DisclosureSEC source: 0001298709-26-000011 · wk-form4_1788563646.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,372,023 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F2 · price: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 40 | $312.23 | $12,489.20 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 11 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,450,253 Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 964 | $311.36 | $300,149.11 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 10 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,450,293 F11 · price: The transaction was executed in multiple trades ranging from $311.07 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,652 | $310.43 | $823,257.71 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,451,257 F10 · price: The transaction was executed in multiple trades ranging from $310.06 to $311.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,784 | $309.49 | $861,620.44 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,453,909 F9 · price: The transaction was executed in multiple trades ranging from $309.04 to $310.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,830 | $308.47 | $1,489,898.99 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,456,693 F8 · price: The transaction was executed in multiple trades ranging from $308.03 to $309.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,461 | $307.68 | $3,526,292.97 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,461,523 F7 · price: The transaction was executed in multiple trades ranging from $307.03 to $308.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 589 | $306.33 | $180,429.43 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472,984 F6 · price: The transaction was executed in multiple trades ranging from $306.00 to $306.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 544 | $304.81 | $165,816.75 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,473,573 F5 · price: The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 176 | $303.17 | $53,357.73 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,474,117 F4 · price: The transaction was executed in multiple trades ranging from $303.05 to $303.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 640 | $302.24 | $193,431.49 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,474,293 F3 · price: The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 320 | $300.75 | $96,240.00 |
DisclosureSEC source: 0001298709-26-000009 · wk-form4_1780699113.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,474,933 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F2 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 920 | $266.56 | $245,230.60 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 10 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,475,253 F12 · price: The transaction was executed in multiple trades ranging from $266.36 to $266.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,439 | $265.59 | $647,773.03 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,476,173 F11 · price: The transaction was executed in multiple trades ranging from $265.235 to $266.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,798 | $264.85 | $2,330,151.18 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,478,612 F10 · price: The transaction was executed in multiple trades ranging from $264.2 to $265.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,043 | $263.70 | $538,741.35 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,487,410 F9 · price: The transaction was executed in multiple trades ranging from $263.19 to $264.1. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,380 | $262.44 | $624,618.62 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,489,453 F8 · price: The transaction was executed in multiple trades ranging from $262.08 to $263. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,962 | $261.41 | $774,289.02 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,491,833 F7 · price: The transaction was executed in multiple trades ranging from $261.07 to $262.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,128 | $260.49 | $814,802.40 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,494,795 F6 · price: The transaction was executed in multiple trades ranging from $260.07 to $261.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,377 | $259.87 | $357,837.55 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,497,923 F5 · price: The transaction was executed in multiple trades ranging from $259.07 to $260.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 470 | $258.38 | $121,438.37 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,499,300 F4 · price: The transaction was executed in multiple trades ranging from $257.89 to $258.765. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:22 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 483 | $257.31 | $124,282.23 |
DisclosureSEC source: 0001298709-26-000004 · wk-form4_1772839326.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,499,770 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. F2 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F3 · price: The transaction was executed in multiple trades ranging from $256.81 to $257.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 18,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 17 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,140 Underlying: Common Stock · 18,140 shares Expires not disclosed F16 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F17 · shares: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F18 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. F18 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 45,249 | $0.00 Strike: $275.64 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 16 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,249 Underlying: Common Stock · 45,249 shares Expires 2036-02-26 F15 · derivative.exercise_date: The stock options vests in four equal annual installments beginning on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionRestricted Stock Units · Derivative | 5,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 15 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,175 Underlying: Common Stock · 5,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026. F6 · derivative.exercise_date: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026. F6 · derivative.expiration_date: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 14 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026. F4 · derivative.exercise_date: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026. F4 · derivative.expiration_date: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionRestricted Stock Units · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · derivative · entry 13 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026. F1 · derivative.exercise_date: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026. F1 · derivative.expiration_date: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 1,820 | $275.64 | $501,664.80 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 10 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,428,155 F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan. F13 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Suma M. Krishnan, upon the vesting of 4,000 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,429,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan. F12 · shares: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025 to the Reporting Person's spouse, Suma M. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026. F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 10,236 | $275.64 | $2,821,451.04 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 8 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,425,975 F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan. F11 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Suma M. Krishnan, upon the vesting of 22,500 PSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 7 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,436,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: 45,000 performance stock units ("PSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Suma M. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026. F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan. F10 · ownership.nature: Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,605 | $275.64 | $718,042.20 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 6 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,253 F7 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 5,725 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 5,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 5 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,502,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 11,942 | $275.64 | $3,291,692.88 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 4 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,497,133 F5 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 26,250 PSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 3 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,509,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 52,500 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,981 | $275.64 | $1,097,322.84 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 2 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,482,825 F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 8,750 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-26-000002 · wk-form4_1772580619.xml · nonDerivative · entry 1 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,486,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period. 8,750 RSUs vested on February 27, 2026. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 23:53 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298709-25-000013 · wk-form4_1764978821.xml · nonDerivative · entry 9 Krishnan Krish S · CIK 0001298709 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,478,056 F10 · kind: Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.